Trial Profile
A Phase 2 Open-label, Multicenter, Randomized, Multidrug Platform Study of Durvalumab (MEDI4736) Alone or in Combination With Novel Agents in Subjects With Locally Advanced, Unresectable (Stage III) Non-small Cell Lung Cancer (COAST)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Mar 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Monalizumab (Primary) ; Oleclumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms COAST
- Sponsors AstraZeneca; MedImmune
- 28 Mar 2024 This trial has been completed in Portugal, according to European Clinical Trials Database record.
- 09 Mar 2024 This trial has been completed in (End date:2023-07-18) according to European Clinical Trials Database record.
- 11 Dec 2023 Status changed from active, no longer recruiting to completed.